Diabetes Scholars Foundation Announces 2015 Scholarship Recipients
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall St ends higher as stocks reclaim some shine
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
Cowen Raises the Price Target on Eli Lilly & Co. (LLY) Following Alimta Patent Win
June 25, 2015 10:42 AM EDTCowen reiterates an Outperform rating on Eli Lilly (NYSE: LLY), and raised the price target to $90.00 (from $85.00), following today's Alimta patent win. The U.K. Court of Appeal ruled that the Alimta (pemetrexed disodium) vitamin supplementation patent would be infringed by generics. Analyst Steve Scala now forecast Alimta ACE (Australia,... More
